According to reports from Zhitong Finance APP, recently, Duality Biologics announced that it has reached an exclusive licensing agreement with GSK for an antibody-drug conjugate (ADC) DB-1324. According to the agreement, GSK will obtain exclusive global rights for the ADC drug (excluding mainland china, Hong Kong, and Macau) to advance the research and commercialization of the therapy.

According to the terms of the agreement, GSK will make a prepayment of 30 million USD and other milestone payments before the exercise to obtain exclusive licensing rights for advancing the research and commercialization of DB-1324 globally (excluding mainland china, Hong Kong, and Macau). If GSK exercises the licensing rights, Duality Biologics will collect exercise fees as well as subsequent milestone payments at different stages of development, regulatory registration, and commercialization, up to a maximum of 0.975 billion USD.

DB-1324 is an innovative ADC molecule developed based on Duality Biologics' unique and clinically validated Duality Immune Toxin Antibody Conjugates (DITAC) platform. It is currently in the preclinical development stage, and its research direction may target gastrointestinal (GI) cancers. In addition, this ADC drug has the potential to be used in combination with several of GSK's anti-tumor products, strategically complementing GSK's oncology product portfolio.